Immunosuppressants and Skin Cancer in Transplant Patients: Focus on Rapamycin

Dermatologic Surgery

Volumn 30, Issue 4 II, 2004, Pages 628-633

  Euvrard, Sylvie ^a   Ulrich, Claas ^b   Lefrancois, Nicole ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; RAPAMYCIN; TACROLIMUS;

CANCER RISK; DRUG ACTIVITY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; REVIEW; SKIN CARCINOGENESIS; SKIN CARCINOMA; SKIN GRAFT; SKIN TRANSPLANTATION; TUMOR GROWTH; ULTRAVIOLET RADIATION;

EID: 1942540090     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2004.30148.x     Document Type: Review

References (60)

1. Euvrard S, Kanitakis J, Claudy A. Skin cancers in organ transplant recipients. New Engl J Med 2003;348:1681-91.
2. Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 2002;160:251-8.
3. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 1995;27:1767-8.
4. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001;137:459-63.
5. Berg D, Otley C. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002;47:1-17.
6. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
7. Cairey-Remonnay S, Humbey O, Mougin C, et al. TP 53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with HPV status. 2002;118:1026-31.
8. McGregor JM, Harwood CA, Brooks L, et al. Relationship between p53 Codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 2002;119:84-90.
9. Marshall SE, Bordea C, Haldar N, et al. Glutathione S-transferase polymorphisms and skin cancer after renal transplantation. Kidney Int 2000;58:2186-93.
10. Ramsay HM, Harden PN, Reece S, et al. Polymorphism in glutathione S-transferases are associated with altered risk of non-melanoma skin cancer in renal transplant recipients: a preliminary analysis. J Invest Dermatol 2001;117:251-5.
11. Alamartine E, Berthoux P, Mariat C, Cambazard F, Berthoux F. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol 2003;120:99-103.
12. Pouteil-Noble C. Immunosuppressive treatments. In: Euvrard S, Kanitakis J, Claudy A, eds. Skin Diseases after Organ Transplantation. Paris: Libbey Eurotext, 1998. p. 175-82.
13. Lampros TD, Cobanoglu A, Parker F, et al. Squamous and basal cell carcinoma in heart transplant recipients. J Heart Lung Transplant 1998;17:586.
14. Mihalov ML, Gattuso P, Abraham K, et al. Incidence of posttransplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996;10:248-55.
15. Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997;29:831-3.
16. Adamson R, Obispo E, Dychter S, et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study. Trans Proc 1998;30:1124-6.
17. Sanchez EQ, Marubashi S, Jung G, et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transplant 2002;8:285-91.
18. Karagas MR, Cushing GL, Greenberg ER, et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001;85:683-6.
19. Lennard L, Thomas S, Harrington CI, Maddocks JL. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985;113:723-9.
20. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992;53:1051-5.
21. Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987;44:429-34.
22. Servilla KS, Burnham DK, Daynes RA. Ability of CsA to promote the growth of transplanted ultraviolet radiation-induced tumors in mice. Transplantation 1987;44:291-5.
23. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177-86.
24. Glover MT, Deeks JJ, Raftery MJ, et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997;349:398.
25. Behrend M, Kolditz M, Kliem V, et al. Malignancies in patients under long-term immunosuppression after kidney transplantation. Transplant Proc 1997;29:834-5.
26. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-8.
27. Bouwes-Bavinck JN, Hardie D, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation 1996;61:715-21.
28. Hojo M, Morimoto T, Maluccio M, et al. CsA induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
29. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or CsA-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997;80:1141-50.
30. Jain AB, Yee LD, Nalesnik MA, et al. Comparative incidence of de novo non lymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998;66:1193-200.
31. Shumacher G, Oidtmann MP, Rosewicz S, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002;34:1392-3.
32. Frezza EE, Fung JJ, Van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997;44:1172-81.
33. Fung JJ, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transplant 2001;7:S109-18.
34. Robson RA, Opelz G, Cecka JM, et al. Risk of PTLD and other malignancies in renal transplant patients treated with MMF: a prospective observational cohort study [abstract]. Am J Transplant 2003;3(Suppl 5):187.
35. Bude K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002;1073-83.
36. Azuma H, Takahara S, Horie S, et al. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY 720 treatment. J Urol 2003;169:2372-7.
37. Azuma H, Horie S, Muto S, et al. Selective cancer cell apoptosis induced by FTY 720: evidence for a Bcl-dependent pathway and impairment in ERK activity. Anticancer Res 2003;23:3183-93.
38. Tanaka T, Takahara S, Hatori M, et al. A novel immunosuppressive drug, FTY 720, prevents the cancer progression induced by CsA. Cancer Lett 2002;181:165-71.
39. Sehgal SN, Molnar-Kimber K, Ocain TD, et al. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 1994;14:1-22.
40. Huang S, Houghton PJ. Resistance to rapamycin: a novel anticancer drug. Cancer Metastasis Rev 2001;20:69-78.
41. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Invest Drugs 2002;3:295-304.
42. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73:1565-72.
43. Brenneisen P, Wenk J, Wlaschek M, Krieg T, Scharffeter-Kochanek K. Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. J Biol Chem 2000;275:4336-44.
44. Yarosh DB, Cruz PD, Dougherty I, et al. FRAP DNA-dependent protein kinase mediates a late signal transduced from ultravioletinduced DNA damage. J Invest Dermatol 2000;114:1005-10.
45. Yarosh DB, Boumakis S, Brown AB, et al. Measurement of UVB-induced DNA damage and its consequences in models of immunosuppression. Methods 2002;55-62.
46. Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
47. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003;63:917-26.
48. Mathew T, Kreis H, Doyen K. Malignancy in renal transplant recipients receiving sirolimus (Rapamune*) maintenance therapy: 2-year follow-up from 5 multicenter studies [abstract]. Transplantation 2002;74(Suppl):131.
49. Yakupoglu Y, Kahan B. Low incidence of malignancy among renal transplant recipients treated with a sirolimus-CsA regimen [abstract]. Am J Transplant 2003;3(Suppl 5):186.
50. Radovancevic B, Vrtovec B. Sirolimus therapy in cardiac transplantation. Transplant Proc 2003;35:171S-6S.
51. Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003;35:193S S-200S.
52. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 5-year experience. Transplant Proc 2003;35:52S-7S.
53. Legendre C, Campistol JM, Squifflet JP, Burke JT. Cardiovascular risk factors for sirolimus compared with CsA: early experience from two randomized trials in renal transplantation. The Sirolimus European Renal Transplant Study Group. Transplant Proc 2003;35 (Suppl 3):151S-3S.
54. Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid oedema in kidney transplant recipients. Transplantation 2001;72:162-4.
55. Aboujaoude WJ, Milgrom ML, Nayee LH, Govani MV. Lymphedema associated with sirolimus in renal transplant recipients [abstract]. Am J Transplant 2003;3(Suppl 5):488.
56. Wadei H, Gruber S, Garnick J, et al. Sirolimus-induced angiodema: report of two cases [abstract]. Am J Transplant 2003;3(Suppl 5):488.
57. Humar A, Harmon JV, Asolati M, et al. Wound complications after kidney transplant-how much are the newer immunosuppression drugs playing a role? [abstract]. Am J Transplant 2003;3(Suppl 5):487.
58. Geissler EK, Guba M, Koehl G, et al. Rapamycin treatment at immunosuppressive doses affects tumor blood vessel circulation [abstract]. Am J Transplant 2003;3(Suppl 5):392.
59. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000;97:4285-90.
60. Butnaru AC, Euvrard S, Kanitakis Lefrançois N, Claudy A. Individual risk of skin cancer development in kidney transplant recipients after the occurence of the first squamous cell carcinoma [abstract]. J Eur Acad Dermatol Venereol 2003;17 (Suppl 3):158.